Microbial Genomics and Novel Antibiotic Discovery: New Technology to Search for New Drugs

Authors: Dougherty, T.J.; Barrett, J.F.; Pucci, M.J.

Source: Current Pharmaceutical Design, Volume 8, Number 13, 1 June 2002 , pp. 1119-1135(17)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

The process of prokaryotic drug discovery has been a model of success for over fifty years, yet the number of exploited bacterial targets is a mere fraction, less than 0.1% of the potential targets (based on total number of bacterial genes identified by gene sequence projects). To better understand the potential for drug intervention, multiple paradigms have been established in the pharmaceutical industry, all with some semblance of commonality and uniqueness to provide proprietary positioning, yet no company has been successful to date in taking a ‘genomics approach’ to the finish line of having a genomics-based drug on the market. Within this overview, we provide a strategic overview of a sample process for the identification, validation and exploitation of novel antibacterial targets ascertained through a bioinformatics-based genomics drug discovery program.

Keywords: microbial genomics; antibiotic discovery; prokaryotic drug; genomics approach; genomics-based drug

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1381612023394782

Publication date: 2002-06-01

More about this publication?

Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.